News

Perampanel Reduced Seizures by 5%-14% in Intractable Cohort


 

FROM THE ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY

Both studies started with 6 weeks of observation to count the number of seizures, then a 6-week titration phase followed by a 13-week maintenance period. Patients continued taking their regular antiepileptic therapy during the studies and were offered enrollment in open-label extension studies after completion of the trials.

Eisai Inc., which is developing perampanel, funded the studies. Dr. French has received research support from Eisai and many other companies manufacturing antiepileptic drugs. Some of her associates in the study also disclosed relationships with Eisai and other companies making antiepileptic drugs.

Pages

Recommended Reading

Sociopathy In Dementia Takes Two Disparate Forms
MDedge Family Medicine
Despite Setbacks, Promising Alzheimer's Treatments Still in Pipeline
MDedge Family Medicine
Triad of Signs, Symptoms May Identify Risk for Parkinson's
MDedge Family Medicine
Safinamide Plus Levodopa May Reduce Dyskinesia in Parkinson's
MDedge Family Medicine
Guideline for Treating Diabetic Nerve Pain Unveiled
MDedge Family Medicine
Low-Intensity Treadmill Exercise Benefits Walking in Parkinson’s Disease
MDedge Family Medicine
Apathy Limits Executive Functioning in Nondemented Parkinson’s Patients
MDedge Family Medicine
Oral Laquinimod Reduced MS Relapses by 23%
MDedge Family Medicine
Neuropsychiatric Symptoms Predict Progression From Mild Cognitive Impairment to Dementia
MDedge Family Medicine
Cerebral Microbleeds Common in Elderly
MDedge Family Medicine

Related Articles